• Scinai Immunotherapeutics signed a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company.
• Contract includes about USD 5.1 million in committed base service fees, with revenue expected across 2026 and 2027.
• Committed customer orders rose to about USD 7.6 million, up about 300% from USD 1.9 million at year-end 2025.
• Additional clinical manufacturing could add an indicative, uncommitted USD 5.85 million in service fees for late 2027 to H1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scinai Immunotherapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610130700PR_NEWS_USPR_____LN70008) on October 13, 2026, and is solely responsible for the information contained therein.